TY - JOUR
T1 - Beyond the Guidelines
T2 - A Narrative Review of Treatments on the Horizon for Migraine in Children and Adolescents
AU - Vanderpluym, Juliana H.
AU - Victorio, M. Cristina C.
AU - Oakley, Christopher B.
AU - Rastogi, Reena G.
AU - Orr, Serena L.
N1 - Publisher Copyright:
© American Academy of Neurology.
PY - 2023/10/31
Y1 - 2023/10/31
N2 - Migraine is common in children and adolescents and can cause significant disability. There are relatively limited evidence-based treatment options available, especially when compared with treatment of migraine in adults. The Pediatric Research Equity Act requires the study of a new drug or biologic in pediatric populations. As such it is mandatory that the newest migraine treatment options available for adults be evaluated in children and adolescents. It will take years before results from clinical trials in pediatric patients become available. In the meantime, there is eagerness among clinicians to seek out the existing evidence that may help provide clarity on utilization of the newer migraine therapies in children and adolescents because many of the currently available, guideline-recommended treatments do not provide benefit for all patients. In this narrative review, the literature regarding onabotulinumtoxinA, neuromodulatory devices, calcitonin gene-related peptide (CGRP) monoclonal antibodies, 5-hydroxytryptamine (1F) agonists (i.e., ditans), and CGRP small-molecule receptor antagonists (i.e., gepants) for the treatment of migraine in children and adolescents will be summarized.
AB - Migraine is common in children and adolescents and can cause significant disability. There are relatively limited evidence-based treatment options available, especially when compared with treatment of migraine in adults. The Pediatric Research Equity Act requires the study of a new drug or biologic in pediatric populations. As such it is mandatory that the newest migraine treatment options available for adults be evaluated in children and adolescents. It will take years before results from clinical trials in pediatric patients become available. In the meantime, there is eagerness among clinicians to seek out the existing evidence that may help provide clarity on utilization of the newer migraine therapies in children and adolescents because many of the currently available, guideline-recommended treatments do not provide benefit for all patients. In this narrative review, the literature regarding onabotulinumtoxinA, neuromodulatory devices, calcitonin gene-related peptide (CGRP) monoclonal antibodies, 5-hydroxytryptamine (1F) agonists (i.e., ditans), and CGRP small-molecule receptor antagonists (i.e., gepants) for the treatment of migraine in children and adolescents will be summarized.
UR - http://www.scopus.com/inward/record.url?scp=85175585238&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85175585238&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000207677
DO - 10.1212/WNL.0000000000207677
M3 - Review article
C2 - 37604658
AN - SCOPUS:85175585238
SN - 0028-3878
VL - 101
SP - 788
EP - 797
JO - Neurology
JF - Neurology
IS - 18
ER -